Springfield, MO

Log in Subscribe

Pfizer may merge off-patent drug business with Mylan

Posted online

Pfizer Inc. is considering a merger of its off-patent drug business with generic drugmaker Mylan, people familiar with the matter told The Wall Street Journal.

Under the proposal, Mylan shareholders would own more than 40% of the new entity and Pfizer shareholders would own the remainder.

Such a deal would create a global company that sells lower-priced pharmaceuticals.

Read more from The Wall Street Journal.


No comments on this story |
Please log in to add your comment
Editors' Pick
Business Spotlight: Finding the Need and Filling It

Good Samaritan celebrates 65 years.

Most Read
Update cookies preferences